source
- Former FDA official says leadership turnover won’t derail push for faster US drug trialsThe Food and Drug Administration has faced a wave of leadership changes this year, creating uncertainty about its ability to keep drug development moving quickly. Industry leaders and regulators, h…
- Allogene CEO David Chang to step down after eight years; former Esperion chief joins PhlowLongtime Allogene chief executive David Chang announced he will leave the role at the end of June, concluding an eight‑year tenure leading the cell‑therapy developer. The company said a successor…